Loading organizations...
Key people at EPS.
EPS was founded in 1983 by Carlalberto Guglielminotti (Co-Founder & CEO).
EPS Corporation is a Red Bank, New Jersey-based company that provides systems engineering, professional services, and technical support to public sector organizations worldwide. Operating as a Woman Owned Small Business, the firm focuses on delivering communications and infrastructure engineering solutions through direct government contracts. The organization structures its service portfolio to meet the operational requirements of its primary customers, which include the United States Armed Forces, federal government agencies, and international civilian organizations. To maintain its technical capabilities and support its worldwide logistics and engineering operations, the company currently employs a workforce of over 250 professionals. Throughout its history, the firm has actively pursued targeted acquisitions to broaden its technological infrastructure and expand its capacity for large-scale federal projects. EPS Corporation was established in 1983 by co-founders Francesco A. Musorrafiti and Antoinette Musorrafiti.
Key people at EPS.
EPS was founded in 1983 by Carlalberto Guglielminotti (Co-Founder & CEO).
EPS Holdings, Inc. is a Tokyo-based company providing comprehensive outsourced solutions to the healthcare industry, primarily through contract research organization (CRO) services, site management organization (SMO) services, contract sales organization (CSO) activities, and related business process outsourcing (BPO) for pharmaceutical companies, medical device manufacturers, and research institutions in Japan and Asia.[1][3] It offers clinical research, IT services for pharma settings, medical device support, MR recruitment and training, medical communications, and additional services like pharmaceuticals R&D, human/animal studies, and consulting for functional foods, serving as a key partner in drug development and clinical trials.[1][3] As of 2021, it operates as a subsidiary of Y&G Limited, with a strong market position including No. 1 share in Japan's SMO business.[1][3]
EPS Holdings traces its roots to 1991, when it started as a software development company in Japan.[1][3] In 1996, it rebranded to EPS Co., Ltd., and by 1999, it pioneered full-fledged CRO operations in Shanghai—marking it as China's first—and launched its SMO business to support clinical trials at medical institutions, later achieving industry-leading market share through mergers.[3] The company expanded into CSO services in 2000, handling medical representative (MR) operations for pharma firms, and became Japan's first CRO to go public in 2001.[3] This evolution from software to a diversified healthcare services powerhouse reflects steady growth across CRO, SMO, CSO, and Asia-Pacific expansion.[1][3]
EPS Holdings rides the global surge in outsourced clinical trials and healthcare R&D, driven by rising drug development complexity, Asia's cost advantages, and pharma's push for efficiency amid regulatory pressures.[1][3] Its early Asia expansion—starting with China in 1999—capitalizes on the region's booming pharma market, where Japan and China lead in trials; this timing positions it ahead of Western CROs entering later.[3] Market forces like aging populations, biotech innovation, and post-pandemic trial acceleration favor its integrated model, reducing pharma costs via localized SMO/CSO/BPO.[1] EPS influences the ecosystem by enabling faster trials (No. 1 SMO share), supporting ventures/universities, and bridging software origins with healthcare tech like IT services.[3]
EPS Holdings is poised for growth in Asia's expanding clinical research market, leveraging its subsidiary status for acquisitions and tech integrations like AI-driven trials or digital health tools. Trends in personalized medicine, real-world evidence, and China-Japan pharma ties will shape its path, potentially boosting CSO demand amid sales force optimization. Its influence may evolve from regional leader to global player, solidifying outsourced healthcare solutions as pharma scales innovation.[1][3]
